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        IgM is the fi  rst Ig isotype to appear during phy-
logeny, ontogeny, and the immune response, 
and has been suggested as a fi  rst line of host de-
fense to pathogens. Serum levels of IgM in mice 
raised under germ-free conditions are similar to 
those of mice maintained under conventional 
housing conditions (  Haury et al., 1997  ). Thus, 
production of preimmune “natural” IgM anti-
body, primarily by CD5  +   B-1 cells, is likely to 
be regulated by mechanisms unrelated to exog-
enous antigen specifi  city. In contrast, antigen-
induced IgM production is mainly derived from 
conventional B-2 cells. The importance of both 
natural and induced IgM antibodies in immune 
responses has been established through recent 
studies of a mutant mouse strain in which 
B cells expressing surface IgM and IgD could 
switch and secrete IgG and IgA, but not IgM, 
antibodies (  Boes et al., 1998a  ;   Ehrenstein et al., 
1998  ). These mutant mice had impaired con-
trol of viral and bacterial infections because of 
ineffi   cient induction of protective IgG antibody 
responses (  Boes et al., 1998b  ;   Ochsenbein et al., 
1999  ;   Baumgarth et al., 2000  ). Thus, these 
fi  ndings indicate that IgM antibody can pro-
foundly infl  uence immune responses and sug-
gest that some of these eff  ects are mediated by 
binding to eff  ector molecules such as Fc recep-
tor (FcR) and complement via its carboxyl-
constant regions. 
  Several FcRs, namely FcR for IgG (Fc    RI/
CD64, Fc    RII/CD32, and Fc    RIII/CD16), 
IgE (Fc    RI), and IgA (Fc    R/CD89), have been 
characterized at both the protein and nucleic 
acid levels (  Ravetch and Nimmerjahn, 2008  ). 
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  Although Fc receptors (FcRs) for switched immunoglobulin (Ig) isotypes have been exten-
sively characterized, FcR for IgM (Fc    R) has defi  ed identifi  cation. By retroviral expression 
and functional cloning, we have identifi  ed a complementary DNA (cDNA) encoding a bona 
fi  de Fc    R in human B-lineage cDNA libraries. Fc    R is defi  ned as a transmembrane sialo-
glycoprotein of     60 kD, which contains an extracellular Ig-like domain homologous to two 
other IgM-binding receptors (polymeric Ig receptor and Fc    /    R) but exhibits an exclusive 
Fc    -binding specifi  city. The cytoplasmic tail of Fc    R contains conserved Ser and Tyr resi-
dues, but none of the Tyr residues match the immunoreceptor tyrosine-based activation, 
inhibitory, or switch motifs. Unlike other FcRs, the major cell types expressing Fc    R are 
adaptive immune cells, including B and T lymphocytes. After antigen-receptor ligation or 
phorbol myristate acetate stimulation, Fc    R expression was up-regulated on B cells but 
was down-modulated on T cells, suggesting differential regulation of Fc    R expression 
during B and T cell activation. Although this receptor was initially designated as Fas apop-
totic inhibitory molecule 3, or TOSO, our results indicate that Fc    R per se has no inhibitory 
activity in Fas-mediated apoptosis and that such inhibition is only achieved when anti-Fas 
antibody of an IgM but not IgG isotype is used for inducing apoptosis. 
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originally designated as TOSO, after a Japanese liquor drunk 
on New Year’s day to celebrate long life and eternal youth 
(  Hitoshi et al., 1998  ). Interestingly, however, the apoptosis in 
this functional assay was induced by ligation of Fas with a 
mouse mAb of IgM isotype (CH11). This immediately raised 
the possibility that the CH11 mAb bound to the Fas via its 
Fab     portion and to the FAIM3/TOSO via its Fc     portion, 
thereby bringing them in close physical proximity in a 
process reminiscent of that described in Fc    RIIb-mediated 
inhibition of BCR signaling by intact IgG anti-     antibodies 
(  Tony and Schimpl, 1980  ;   Ravetch and Nimmerjahn, 2008  ). 
In contrast, FcR for IgM (Fc    R) has defi  ed genetic identifi  -
cation, although the existence of Fc    R on B, T, NK, and 
phagocytic cells has been suggested for >30 yr with variable 
and confl  icting results (  Basten et al., 1972  ;   Moretta et al., 
1975  ;   Lamon et al., 1976  ;   Ferrarini et al., 1977  ;   Moretta et al., 
1977  ;   Pichler and Knapp, 1977  ;   Santana, 1977  ;   Haegert, 
1979  ;   Reinherz et al., 1980  ;   Uher et al., 1981  ;   Sanders et al., 
1987  ;   Mathur et al., 1988a  ;   Mathur et al., 1988b  ;   Ohno et al., 
1990  ;   Nakamura et al., 1993  ;   Pricop et al., 1993  ;   Rabinowich 
et al., 1996  ). In addition to the aforementioned classical FcRs, 
several other receptors expressed on unique cell types also 
bind Ig molecules: (a) neonatal FcR for IgG (FcRn) on intes-
tinal epithelium, placenta, and endothelium (  Roopenian and 
Akilesh, 2007  ); ( b) low affi   nity Fc    R (Fc    RII/CD23) on B cells 
and macrophages (  Conrad, 1990  ); (c) polymeric Ig receptor 
(pIgR) on mucosal epithelium (  Kaetzel, 2005  ); and (d) FcR 
for IgA and IgM (Fc    /    R;   Shibuya et al., 2000  ) on follicular 
dendritic cells (  Kikuno et al., 2007  ). Although the latter two 
receptors bind polymeric IgA and IgM, their biochemical 
features and cellular distribution are distinct from those of 
the Fc    R that we have previously characterized on B and 
T cells in humans (  Sanders et al., 1987  ;   Ohno et al., 1990  ; 
  Nakamura et al., 1993  ). In this paper, we have identifi  ed a 
cDNA encoding a bona fi  de Fc    R that is defi  ned as trans-
membrane protein of     60 kD expressed predominantly on 
B and T lymphocytes. 
  RESULTS 
  Molecular cloning of the Fc    R 
  Our previous cellular and biochemical studies provided 
strong evidence for the existence of an Fc    R that is expressed 
constitutively on chronic lymphocytic leukemia (CLL) B cells 
and inducibly on pre–B cell lines (  Sanders et al., 1987  ;   Ohno 
et al., 1990  ). To identify the gene encoding the putative 
Fc    R, two diff  erent cDNA libraries from CLL B cells and a 
PMA-activated 697 pre–B cell line were constructed in a ret-
roviral expression vector and then introduced into mouse 
T cell line BW5147. Transduced cells exhibiting IgM bind-
ing were enriched by FACS and subcloned. Many of the sin-
gle cell–derived subclones from both cDNA libraries bound 
IgM (  Fig. 1 A  ).   RT-PCR analysis revealed that a DNA frag-
ment of     2 kb was specifi  cally amplifi  ed only from IgM-
binding subclones (  Fig. 1 B  ), and their nucleotide sequence 
analyses defi  ned an identical 1,173-bp open reading frame 
(CLL- and PMA-activated 697 pre–B cell–derived Fc    R 
cDNA available from GenBank/EMBL/DDBJ under acces-
sion nos.   GQ160900   and   GQ160901  , respectively;   Fig. S1  ). 
Basic local alignment search technique database analysis re-
vealed that the isolated Fc    R cDNA was identical to that of 
the previously described human Fas apoptotic inhibitory 
molecule 3 (FAIM3; available from GenBank/EMBL/DDBJ 
under accession no.   NM_005449  ), except for one nucleotide 
diff  erence at a position reported as a synonymous single nu-
cleotide polymorphism. FAIM3 was identifi  ed in a similar 
retroviral cDNA library–based functional assay as a potent 
inhibitor of Fas/CD95-induced apoptotic signaling and was 
    Figure 1.     Isolation of IgM-binding subclones and identifi  cation of 
cDNA inserts.   (A) Cells transduced by the retroviral expression construct 
containing CLL-derived (top) or PMA-activated 697 pre–B cell–derived 
(bottom) cDNA libraries were enriched for IgM binding by FACS and sub-
cloned for limiting dilution. Three representative subclones from each 
library are shown for their IgM-binding activity or lack of binding, as de-
termined by fl  ow cytometry. (B) Agarose gel electrophoresis analysis of 
RT-PCR products. RNA isolated from nontransduced control BW5147 
T cells (lane 1) and from IgM-binding (lanes 3–5 and 7–9) or IgM-
nonbinding (lanes 2 and 6) subclones from CLL-derived (lanes 2–5) and 
PMA-activated 697 pre–B cell–derived (lanes 6–9) cDNA libraries were 
subjected to RT-PCR as described in Materials and methods. Amplifi  ed 
products were electrophoresed in 0.7% agarose and stained with ethid-
ium bromide. Lane 10 is a PCR control without a fi  rst-strand cDNA tem-
plate.   Hin dIII-digested      DNA was used as a size marker. The experiments 
were performed once for A and twice for B.     JEM VOL. 206, November 23, 2009 
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  The   FAIM3/TOSO   gene encodes a bona fi  de Fc    R 
  To reconcile the confl  icting functions of FAIM3/TOSO and 
our functionally defi  ned Fc    R, an     1.2-kb cDNA contain-
ing the protein coding region of FAIM3/TOSO/Fc    R was 
PCR amplifi  ed from PMA-activated 697 pre–B cells, sub-
cloned along with a GFP cDNA into the bicistronic retrovi-
ral vector and then transduced into BW5147 T cells. The 
resultant GFP  +   transductants clearly exhibited IgM binding 
(  Fig. S2  ), thereby confi  rming that FAIM3/TOSO is an IgM 
receptor. The Fc    R cDNA is predicted to encode a 390-aa 
type I membrane protein (17-aa signal peptide, 236-aa extra-
cellular region, 19-aa transmembrane segment, and 118-aa 
cytoplasmic tail). The N-terminal half of the extracellular re-
gion contains a single V-set Ig-like domain with homology 
to both the pIgR and Fc    /μR (see next section), but the re-
maining extracellular region has no identifi  able domain fea-
tures (  Fig. S3  ). There are no N-linked glycosylation motifs in 
the extracellular region, consistent with our previous bio-
chemical characterization of the Fc    R (  Ohno et al., 1990  ). 
The mature core peptide is predicted to have an   M    r   of     41 kD 
and an isoelectric point (pI) of     9.9. 
  A quantitative inhibition immunofl  uorescence assay with 
various Ig isotypes and IgM fragments as inhibitors revealed 
that IgM and its Fc  5  μ fragments consisting mostly of C    3/
C    4 domains inhibited the binding of a biotin-labeled hu-
man IgM to Fc    R  +   BW5147 T cells in a dose-dependent 
manner, whereas the Fabμ fragments and other human Ig 
isotypes (IgG  1-4  , IgA  1,2  , IgD, and IgE) did not, thereby con-
fi  rming the Fc     specifi  city of the Fc    R (  Fig. 2 A  ).     Fig. 2 B   
shows a representative inhibition profi  le for IgM binding 
with an eightfold excess of inhibitors. The inability of Fc    R 
to bind polymeric IgA clearly indicates that Fc    R is distinct 
from pIgR and Fc    /μR, both of which are shown to bind 
IgM and polymeric IgA. Moreover, the lack of binding to 
aggregated IgG further confi  rms the unique IgM isotype 
specifi  city of this receptor. Interestingly, mouse IgM bound 
better to the human Fc    R than human IgM, and essentially 
identical Fc    R binding was observed with IgM     and IgM     
ligands irrespective of the presence of Ca  2+  /Mg  2+  . The af-
fi  nity of IgM/Fc    R binding was estimated by Scatchard 
plot analysis using   125  I-labeled human IgM and Fc    R  +   
BW5147 T cells. Assuming a 1:1 stoichiometry of pentam-
eric IgM ligand to Fc    R, this analysis revealed a strikingly 
high binding affi   nity of 10.8 ± 9.2 nM (mean ± SD from 
four experiments with two diff  erent human IgM myeloma 
proteins). Pretreatment of Fc    R  +   cells with neuraminidase 
slightly enhanced IgM binding, suggesting a role of sialic 
acid in this interaction, as reported previously by others 
    Figure 2.     Evaluation of the Ig isotype specifi  city of the Fc    R.  
(A) Fc    R cDNA–transduced BW5147 T cells were preincubated with various 
concentrations of inhibitor paraproteins of human origin (IgM, IgG  1-4 , 
IgA  1-2  , IgD, IgE, Fab    , and Fc  5    ) and incubated with 4 μg/ml of biotin-
labeled human IgM    . Bound biotinylated IgM was detected by addition of 
PE-labeled SA. Stained cells were analyzed by fl  ow cytometry. Results are 
expressed as the percent mean fl  uorescence intensity (MFI) estimated as 
follows: 100 × ([X of IgM binding with inhibitors      X of background 
control]/[X of IgM binding without inhibitors      X of background control]), 
where X indicates the MFI values. Because there were no signifi  cant dif-
ferences among each subclass of IgG and IgA, the results from all four 
IgG subclasses and two IgA subclasses have been combined as IgG and 
IgA, and the mean values are presented for simplicity. (B) Representative 
binding inhibition profi  les. Fc   R +   BW5147 T cells were incubated fi  rst 
with an eightfold excess of the indicated inhibitor proteins and then with 
4 μg/ml of biotin-labeled human IgM    . The dotted, dashed, and continu-
ous lines indicate the immunofl  uorescence profi  les for background con-
trols, IgM binding without inhibitors, and IgM binding with the test 
inhibitors, respectively. (C) Control and Fc   R +   BW5147 cells were incu-
bated with culture supernatants containing the indicated concentrations 
of monomeric (m) or pentameric (p) IgM anti–mouse RBC mAb before 
developing with biotin-labeled anti–mouse      mAb and APC-SA. These 
experiments were performed at least twice.     
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ceptors. Arg63 and Asp86 are also completely conserved, but 
Trp37 is found only in the pIgR and Fc    /    R. Several other 
residues (Gly6, Tyr24, Val29, Arg31, Lys35, Tyr55, and 
Leu101) are also conserved in pIgR and Fc    /    R but not in 
Fc    R. A major diff  erence between Fc    R and the other two 
receptors is in the CDR1 region. The CDR1 of the pIgR 
from six diff  erent species consists of 9 aa (Pro25 to Thr33), 
and this is also the case in the Fc    /    R from two diff  erent 
species. In contrast, the corresponding region of the Fc    R 
from seven diff  erent species consists of 5 aa and has a non-
charged residue (Met, Leu, or Thr) at the position corre-
sponding to Arg31, which has been shown to be solvent 
exposed and possibly to interact directly with polymeric IgA 
in the human pIgR (  Hamburger et al., 2004  ). These results 
suggest a structural basis for the distinct mode of IgM inter-
actions with Fc    R versus pIgR and Fc    /    R. 
  Conserved Ser and Tyr residues in the cytoplasmic tail 
of Fc    R 
  A charged His residue is adjacent to or within the putative 
19-aa transmembrane segment of Fc    R from all species ex-
amined except for the bovine (  Fig. 4  ).   The 118-aa cytoplasmic 
(  Pricop et al., 1993  ). Higher concentrations (>100-fold) 
were required for binding of IgM monomers to the Fc    R  +   
cells than IgM pentamers, indicating the importance of IgM 
ligand confi  guration (  Fig. 2 C  ). Collectively, these results 
indicate that the previously identifi  ed FAIM3/TOSO is an 
authentic Fc    R with exclusive and high affi   nity  binding 
specifi  city for the Fc portion of IgM. 
  The Ig domain of Fc    R is similar but distantly related 
to that of pIgR and Fc    /μR 
    FCMR   is a single copy gene located on chromosome 1q32.2, 
adjacent to two other IgM-binding receptor genes,   PIGR   
and   FCAMR.   The Ig-like domain of FAIM3/TOSO/Fc    R 
is thought to be involved in the binding of agonistic IgM 
anti-Fas mAb (  Hitoshi et al., 1998  ). A comparison of the 
protein sequence of the Ig-binding domains of Fc    R, pIgR, 
and Fc    /    R to the pIgR structural data reported by 
  Hamburger et al.   (  2004  ) provided some potential insight into 
ligand specifi  city (  Fig. 3  ).   In addition to a disulfi  de bond 
between Cys22 and Cys92 linking the two   	   sheets (B and 
F strands), a second disulfi  de bond between Cys38 and Cys46 
linking the C and C  
   strands is also conserved in all three re-
    Figure 3.     aa sequence alignment of IgM-binding receptors.   The Ig-binding domains of pIgR, Fc   /   R, and Fc    R from several species were aligned 
using the CLUSTAL W multiple alignment program (  Thompson et al., 1994  ). aa identity is indicated by dots and gaps are indicated by dashes. Residues 
conserved in all three receptors and in pIgR and Fc   /   R are highlighted in yellow and red, respectively. The numbers indicate the aa position from the 
N terminus of the Ig-binding domain of human pIgR. These sequences are available from GenBank/EMBL/DDBJ under the following accession nos.: pIgR of 
human (hu;   P01833  ), rabbit (rb;   P01832  ), mouse (mo;   O70570  ), rat (rt;   P15083  ), bovine (bo;   P81265  ), and chicken (ch;  AAP69798 );  Fc  /   R of human 
(  AAL51154  ) and mouse (  NP_659209  ); and Fc    R of human (  NP_005440  ), chimpanzee (cm;   XP_001165341  ), monkey (mn;   XP_001084243  ), bovine 
(  XP_588921  ), dog (do;   XP_547385  ), mouse (  NP_081252  ), and rat (  Q5M871  ).     JEM VOL. 206, November 23, 2009 
Article
2783
phosphoserine of PKC substrates. Phosphorylation of both 
serine and tyrosine residues was clearly demonstrated in 
pervanadate-treated cells but not in untreated cells (  Fig. 5 A  ).   
Interestingly, the serine-phosphorylated Fc    R migrated at 
    52 kD, whereas most of the tyrosine-phosphorylated Fc    Rs 
migrated at     60 kD and, to a lesser extent, at     52 kD. When 
these membranes were reprobed with anti-Fc    R mAb spe-
cifi  c for its extracellular epitope, we found that in resting cells 
Fc    R was present as a major band of     60 kD, which is con-
sistent with the   M    r   of the cell-surface Fc    R (see Fig. 7), along 
with a minor band of     45 kD, but in pervanadate-treated cells 
the Fc    R was resolved as a major band of     52 kD together 
with multiple minor species of various sizes. When Fc    R was 
cross-linked with preformed immune complexes consisting of 
IgM and F(ab  
  )  2   fragments of anti-     mAb, phosphorylation of 
both serine and tyrosine residues of the     52 kD Fc    R was 
also demonstrated as early as 3 min after ligation. The serine 
phosphorylation became more prominent at 30 min after 
ligation, whereas tyrosine phosphorylation was diminished 
by that time point (  Fig. 5 B  ). In contrast to the eff  ects seen 
with pervanadate treatment, tyrosine-phosphorylated     60-kD 
Fc    R was not observed in the lysates of receptor-ligated 
cells. Reprobing of these membranes with anti-Fc    R mAb 
revealed the presence of both     60- and     52-kD Fc    R 
proteins as well as minor, but discrete, bands of     45 and 
    63 kD. Collectively, these fi  ndings suggest that the con-
served serine and tyrosine residues seen in the cytoplasmic tail 
of Fc    R are indeed potentially phosphorylated upon re-
ceptor ligation and that the phosphorylated Fc    R protein 
migrates diff  erently on SDS-PAGE compared with its un-
phosphorylated form. 
tail is composed of a basic aa-rich region, a Pro-rich region, 
two conserved Cys residues, and an acidic aa-rich region in 
all seven diff  erent Fc    Rs. Of the Ser residues, fi  ve are com-
pletely conserved and an additional four are highly conserved 
among these Fc    Rs, and some of them are potential sites for 
protein kinase C (PKC) phosphorylation (R/K  1-3  -X  0-2  -S/
T-X  0-2  -R/K  1-3   or R/K-X-S-Z-R/K, where Z represents a 
hydrophobic aa residue) or casein kinase 2 phosphorylation 
(S/T-X  2  -D/E). Three Tyr residues are also completely con-
served among these Fc    Rs, but none of them (I/V-Y315-S/
T-A-C, S-C-E/D-Y361-V-S, and S-D-D-Y385-I/V-N-V/I) 
match the immunoreceptor tyrosine-based activation motif 
(D/E-X  2  -Y-X  2  -L/I-X  6-8  -Y-X  2  -L/I), inhibitory motif (I/V-
X-Y-X  2  -L/V), or switch motif (T-X-Y-X  2  -V/I). However, 
if phosphorylated, the most carboxyl tyrosine is a potential 
binding site (pY-X-N-X) for the Src homology 2 domains of 
growth factor receptor–bound protein 2 and growth factor 
receptor–bound protein 2–related adaptor protein, as observed 
in transmembrane adaptor proteins, including linker for acti-
vation of T cells and non–T cell activation linker (  Horejsí 
et al., 2004  ). These fi  ndings indicate a quite distinct feature of 
the Fc    R cytoplasmic tail compared with other FcRs, in 
which the Ig ligand binding chains are usually devoid of con-
served Tyr residues except for Fc    RIIA and Fc    RIIB. 
  To determine whether these conserved Ser and Tyr resi-
dues are phosphorylated upon stimulation, Fc    R  +   BW5147 
T cells were treated with a tyrosine phosphatase inhibitor, per-
vanadate, or with preformed IgM immune complexes to cross-
link Fc    R. The Fc    R was immunoprecipitated from the 
lysates of resting or activated cells and analyzed by immuno-
blotting with antibodies specifi  c for phosphotyrosine or the 
    Figure 4.     aa sequence alignment of the transmembrane and cytoplasmic regions of Fc    Rs.   aa sequences of the transmembrane segments 
and cytoplasmic tails of Fc    R from seven different species are aligned. aa identity is indicated by dots, and a deletion is indicated by dashes. The pre-
dicted transmembrane region is highlighted in red. Conserved serine and tyrosine residues are also highlighted in blue and yellow, respectively. The 
numbers indicate the aa position from the fi  rst Met residue of human Fc    R. The GenBank/EMBL/DDBJ accession nos. for these Fc    Rs are the same as 
those in   Fig. 3  . Chimp, chimpanzee.     2784 Fc     receptor identity in humans   | Kubagawa et al. 
tor with the IgG  3   antibody induced apoptosis in all three cell 
types, including the Fc    R  +  GFP  +   cells. Notably, ligation of 
Fc    R and Fas with the corresponding mAbs either in the 
absence (i.e., separate ligation of each receptor) or presence 
of a common secondary reagent (i.e., coligation of both re-
ceptors) had no demonstrable eff  ects on the IgG  3   anti-Fas mAb–
induced apoptosis of Fc    R  +  GFP  +   cells. Essentially identical 
results using IgM versus IgG  3   anti-Fas mAb were also ob-
tained with EBV-transformed B cell lines expressing both 
endogenous Fc    R and Fas on their cell surface (unpublished 
data). Collectively, these fi  ndings indicate that Fc    R has no 
intrinsic activity to inhibit Fas-mediated apoptosis, but they 
raise the interesting possibility that IgM anti-Fas autoanti-
body, if present in individuals with autoimmune disorders, 
could interrupt Fas-mediated signaling via Fc    R in vivo. 
  To determine if Fc    R could also aff  ect apoptosis medi-
ated through the BCR, the same retroviral constructs as used 
for Jurkat cells were transduced into a mouse immature B cell 
line, WEHI231, and a human germinal center B cell line, 
Ramos, both of which are negative for Fc    R expression and 
are known to undergo apoptosis after BCR cross-linking. 
However, unlike the Jurkat T cell line, no cell lines of either 
type that stably expressed both Fc    R and GFP were ob-
tained after multiple attempts in diff  erent laboratories (un-
published data), whereas control GFP  +   cell lines were easily 
established. Even after enriching GFP  hi   cells by FACS or by 
antibiotic selection, the established cell lines were found to 
express low levels of GFP and no cell-surface expression of 
Fc    R. Flow cytometric analysis of these B cell lines shortly 
  Fc    R per se has no antiapoptotic activity 
  To determine whether Fc    R inhibits Fas-mediated apopto-
sis as originally described for FAIM3/TOSO (  Hitoshi et al., 
1998  ), retroviral constructs containing both Fc    R and GFP 
cDNAs or only the GFP cDNA were transduced into the 
apoptosis-prone Jurkat human T cell line. Cells expressing 
comparable levels of GFP were enriched from each transduc-
tant by FACS, and the Fc    R/GFP transductant was found to 
express relatively high levels of cell-surface Fc    R as deter-
mined by both receptor-specifi  c mAbs (see next section) 
and IgM ligand binding ( Fig. 6 A ).   The resultant Fc   R  +  GFP  +   
or GFP  +   Jurkat cells and nontransduced Jurkat cells as an 
additional control were then subjected to apoptosis assays 
using agonistic anti-Fas mAbs of the IgM or IgG  3   isotype. 
Cross-linkage of Fas with the IgM antibody induced robust 
early (annexin V  +  /7-aminoactinomycin D [7-AAD]       ) and late 
(annexin V  +  /7-AAD  +  ) apoptotic cells as well as dead cells 
(annexin V       /7-AAD  +  ) in the nontransduced Jurkat cells and 
the GFP  +   cells, but not in the Fc    R  +  /GFP  +   cells (  Fig. 6 B  ). 
This result is consistent with the previously reported anti-
apoptotic activity of FAIM3/TOSO (  Hitoshi et al., 1998  ). It 
should be noted, however, that addition of control IgM of 
either human or mouse origin at a 100-fold molar excess into 
these cultures did not make the Fc    R  +  /GFP  +   cells suscepti-
ble to IgM anti-Fas mAb-induced apoptosis, suggesting that 
the simultaneous dual binding to Fas and Fc    R (i.e., cis in-
teraction) is dominant over the single binding to Fc    R (i.e., 
trans interaction) in this apoptosis model (  Fig. S4  ). Unlike 
the eff  ect seen with IgM anti-Fas mAb, ligation of Fas recep-
    Figure 5.     Tyrosine and serine phosphorylation of Fc    R upon stimulation.   (A and B) BW5147 T cells stably expressing human Fc    R were incubated 
in the presence (+) or absence (    ) of 100 μM pervanadate for 15 min (A) or with the preformed IgM immune complexes for the indicated time periods 
(min) at 37°C (B) before cell lysis. Fc    R was immunoprecipitated from cleared lysates with anti-Fc    R (HM14) or control (Cont.) mAb–coupled beads, re-
solved on SDS–10% PAGE under reducing conditions, transferred onto membranes, and immunoblotted with rabbit antibody specifi  c for phosphoserine of 
PKC substrates along with HRP-labeled goat anti–rabbit Ig antibody (anti-PKC P-Ser) or with HRP-labeled antiphosphotyrosine mAb (anti–P-Tyr) before 
visualization by ECL. After dissociating blotted antibodies, membranes were reprobed with biotin-labeled anti-Fc    R mAbs along with HRP-labeled 
SA (anti-Fc    R). These experiments were performed at least three times.   M  r   is shown in kilodaltons.     JEM VOL. 206, November 23, 2009 
Article
2785
CD11a were also unaff  ected. We extended this analysis to the 
697 pre–B cell line. Consistent with our previous IgM-bind-
ing results (  Ohno et al., 1990  ), these cells do not constitu-
tively express cell-surface Fc    R, but its expression could be 
induced by PMA treatment (  Fig. S5  ). After GPI-PLC treat-
ment, the surface levels of Fc    R and CD19 on PMA-acti-
vated 697 pre–B cells were unchanged, whereas the expression 
of GPI-anchored CD73 was reduced by     50% (  Fig. 7 B  ). 
Thus, these fi  ndings indicate that Fc    R is an authentic trans-
membrane protein, consistent with the predicted structure 
encoded by the Fc    R cDNA. 
  To determine the   M    r   of Fc    R, we performed SDS-PAGE 
analysis of biotinylated cell-surface proteins that were precipi-
tated from membrane lysates with anti-Fc    R mAbs and IgM 
ligands. A major protein with an   M    r   of     60 kD was precipi-
tated from the Fc    R-bearing but not control BW5147 T cells 
with both probes (  Fig. 7 C  ). The same   M    r   estimate was ob-
tained under both reducing and nonreducing conditions, indi-
cating that there are no interchain disulfi  de linkages of Fc    R 
with itself or other proteins. Removal of sialic acid residues 
with neuraminidase from the     60-kD Fc    R resulted in a de-
crease in   M    r   to     50 kD. The cell-surface Fc    R isolated from 
PMA-activated 697 pre–B cells and normal adult blood mono-
nuclear cells (MNCs) had an identical   M    r   of     60 kD, consis-
tent with our previous size estimates (  Sanders et al., 1987  ; 
  Ohno et al., 1990  ;   Nakamura et al., 1993  ). An additional mi-
nor band of     40 kD was occasionally identifi  ed in the precipi-
tates from membrane lysates of Fc    R  +   BW5147 T cells with 
anti-Fc    R mAbs irrespective of detergents used (NP-40, digi-
tonin, or CHAPS). The molecular identity of this 40-kD 
after transduction revealed that forced expression of Fc    R 
resulted in down-modulation of their cell-surface IgM, pre-
sumably because of its ligation with the Fc    R, thereby lead-
ing to loss of the Fc    R  +  GFP  +   cell population. Thus, these 
findings suggest that the ectopic expression of Fc    R on 
WEHI231 and Ramos B cell lines triggers BCR-mediated 
apoptosis as a consequence of direct interaction between the 
Fc    R and membrane-bound IgM molecules. 
  Fc    R is an     60-kD transmembrane protein 
  Two hybridoma mAbs specifi   c for human Fc    R, HM7 
(    2b    ), and HM14 (    1    ) were established from mice immu-
nized with Fc    R  +   BW5147 T cells and were used along 
with the IgM ligand for biochemical characterization of the 
receptor. The HM7 mAb appeared to recognize an epitope 
near the IgM ligand binding site, because HM7 antibody 
binding was significantly inhibited by preincubation of 
Fc    R  +   cells with IgM, whereas HM14 binding was not (un-
published data). Our earlier biochemical analysis revealed 
that Fc    R on B-lineage cells could be attached to the plasma 
membrane via a glycosylphosphatidylinositol (GPI) linkage 
(  Ohno et al., 1990  ;   Nakamura et al., 1993  ), but the structure 
predicted by the cDNA is of a transmembrane protein. We 
thus reexamined this issue using a highly purifi  ed GPI-spe-
cifi  c phospholipase C (GPI-PLC). After GPI-PLC treatment, 
the surface expression of the GPI-anchored Thy-1 on Fc    R  +   
BW5147 T cells was reduced by     65%, whereas surface 
Fc    R levels were unaff  ected as determined by staining with 
both anti-Fc    R mAbs and the IgM ligand (  Fig. 7 A  ).   As ex-
pected, levels of the control transmembrane glycoprotein 
    Figure 6.     Role of Fc    R in Fas-mediated apoptosis of Jurkat T cells.   (A) Jurkat cells transduced without (none) or with the bicistronic retroviral 
construct containing GFP cDNA only (GFP) or both Fc    R and GFP cDNAs (Fc    R/GFP) were incubated with biotin-labeled isotype-matched control mAb 
(left), HM14 anti-Fc    R mAb (middle), or human IgM (right), and then with APC-SA before analysis by FACSCalibur. Note the comparable levels of GFP in 
both GFP and Fc    R/GFP transductants, and the expression of Fc    R on the Fc    R/GFP transductant as determined by anti-Fc    R reactivity and IgM ligand 
binding. (B) These three cell lines were incubated at 37°C for 24 h with agonistic anti–human Fas mAbs of mouse IgM     (CH11 clone; 10 ng/ml) or IgG  3    
isotype (2R2 clone; 0.3 μg/ml). Cells were stained with 7-AAD and APC-labeled annexin V before identifi  cation of early (annexin V  + /7-AAD      ) and late 
(annexin V  + /7-AAD +  ) apoptotic and dead (annexin V      /7-AAD +  ) cells by FACSCalibur. Note the resistance of Fc    R/GFP transductant to IgM but not IgG3 
anti-Fas mAb–induced apoptosis. Numbers indicate percentages of cells. These experiments were performed more than three times.    2786 Fc     receptor identity in humans   | Kubagawa et al. 
of staining with the HM14 mAb was higher than with the 
HM7 mAb (unpublished data), an observation consistent 
with the fi  nding that the HM7 epitope is sensitive to IgM 
ligand binding; given its high affi   nity, the Fc    R is likely to 
be occupied by IgM in vivo. Clearly, mAb reactivity was a 
more sensitive assay for the detection of Fc    R than ligand 
binding using biotin-labeled human IgM, although the sen-
sitivity of the ligand-binding assay could be increased by us-
ing mouse IgM    , biotin-labeled rat anti–mouse      mAb and 
streptavidin (SA)-PE. In addition to B and T cells, CD56  +  /
CD3        NK cells also expressed Fc    R at relatively low 
density. Other blood cell types, CD14  +   monocytes, CD13  +   
granulocytes, erythrocytes, and platelets, did not express 
Fc    R at detectable levels (  Fig. S7  ). 
  Notably, overnight culture of blood MNCs in IgM-free 
media enhanced Fc    R expression especially by T cells (  Fig. 8 B  ), 
consistent with our previous IgM-binding data (  Nakamura 
et al., 1993  ). Curiously, this enhancement was more evident 
for the cell preparations from the tonsils and spleen than from 
blood. Freshly isolated tonsillar MNCs, including B and T cells, 
had no reactivity with either anti-Fc    R mAbs or IgM li-
gands, but after overnight culture, there was clear-cut expres-
sion of Fc    R on the surface of the CD19  +   B cells and the 
CD4  +   and CD8  +   T cells (  Fig. 8 C  ). Most follicular (IgD  +  /
CD38       ) and memory (IgD       /CD38       ) B cells expressed Fc    R, 
whereas only a small subpopulation of the germinal center 
(IgD       /CD38  +  ) and pregerminal center (IgD  +  /CD38  +  ) B cells 
expressed Fc    R, consistent with our RT-PCR data. Many 
protein is presently unknown. Although the predicted pI of 
Fc    R is     9.9, the     60-kD Fc    R was resolved into a spot 
with a pI of     5 by two-dimensional gel electrophoresis analy-
sis (unpublished data), consistent with our previous fi  nding that 
Fc    R is sialylated (  Ohno et al., 1990  ). 
  Fc    R is predominantly expressed by both B 
and T lymphocytes 
  To determine the cellular distribution of Fc    R, we fi  rst con-
ducted RT-PCR analysis of various tissues and a panel of 
representative cell lines. Fc    R transcripts were restricted to 
hematopoietic and lymphoid tissues, including the blood, 
bone marrow, tonsils, spleen, and appendix. Fc    R transcripts 
were detected in both CD4  +   and CD8  +   T cells from blood as 
well as in all subsets of tonsillar B cells, although the transcript 
levels appeared highest in the follicular and memory B cells 
(  Fig. S6  , top). Among the cell lines, 697 pre–B cells expressed 
Fc    R transcripts, although they did not constitutively ex-
press cell-surface Fc    R protein (Fig. S5). Another pro–/pre–
B cell line (REH) and some B cell lines (Ramos and the 
EVB-transformed line BDB-14.4) also contained Fc    R 
mRNA (Fig. S6, bottom). 
  Next, we examined cell-surface Fc    R expression by 
immunofl  uorescence analysis using receptor-specifi  c mAbs 
and IgM ligands. In normal adult blood samples, Fc    R was 
clearly expressed on CD19  +   B cells and on the CD4  +   and 
CD8  +   T cells, although there was no discrete demarcation 
between Fc    R  +   and Fc    R        T cells (  Fig. 8 A  ).   The intensity 
    Figure 7.     Biochemical characterization of Fc    R molecules.   (A and B) GPI-PLC treatments. BW5147 T cells stably expressing human Fc    R (A) and 
PMA-activated 697 pre–B cells (B) were incubated with PBS (blue) or 10 U/ml GPI-PLC (red) for 30 min at 30°C, and then examined for the expression of 
Fc    R by anti-Fc    R mAb or IgM ligand binding along with the expression of Thy-1 and CD11a (A) or of CD73 (ecto-5  
  -nucleotidase) and CD19 (B). A con-
trol sample was kept on ice during this treatment without GPI-PLC (green). Note the signifi  cant reduction in MFI of Thy-1 and CD73 but not of CD11a, 
CD19, Fc    R, and IgM-binding profi  les after GPI-PLC treatment. (C) SDS-PAGE analysis of cell-surface proteins. Plasma membrane proteins on control 
(BW) and Fc    R-bearing BW5147 T cells (Fc    R) were labeled with biotin, quenched, and incubated with mouse    1    control (Cont.) or anti-Fc   R  (HM14) 
mAbs or mouse IgM     ligand before washing and solubilization in 1% NP-40 lysis buffer containing protease inhibitors. The mAb-bound cell-surface pro-
teins were captured by addition of beads coupled with rat anti–mouse      mAb (187.1 clone) and resolved on SDS–10% PAGE under nonreducing (not de-
picted) and reducing conditions, followed by transfer onto membranes, blotting with HRP-SA, and visualization by ECL. The same results were obtained 
with the HM7 anti-Fc    R mAbs. The arrow indicates Fc    R. The experiments were performed 3 times for A and B and >10 times for C.     JEM VOL. 206, November 23, 2009 
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  To further examine the eff  ects of cellular activation on 
surface Fc    R expression, blood MNCs were activated with 
various stimuli. Treatments of blood B cells with anti-μ 
mAb or PMA for 24 h resulted in an     2.2-fold increase in 
the cell-surface Fc    R level in comparison to that on B cells 
cultured in media only (unpublished data). In contrast, treat-
ment of blood T cells with anti-CD3 mAb or PMA for 
24–72 h reduced the cell-surface Fc    R level by     90%, sug-
gesting that signaling through antigen receptors on B and 
T cells has distinct modulating eff  ects on Fc    R expression. 
Consistent with previous observations (  Ferrarini et al., 1977  ; 
  Pichler and Knapp, 1977  ;   Sanders et al., 1987  ), there was 
enhanced Fc    R expression by CLL B cells from three ran-
domly selected patient blood samples (  Fig. S8  ). Collectively, 
these fi  ndings indicate that, in striking contrast to other 
FcRs, Fc    R is predominantly expressed by cells of the adaptive 
immune system. Moreover, the cell-surface levels of Fc    R 
CD4  +   T cells and the majority of CD8  +   T cells clearly ex-
pressed cell-surface Fc    R after culture. After overnight cul-
ture, the proportion of Fc    R  +   B, CD4  +   T, CD8  +   T, and 
NK cells in the spleen was similar to that in blood samples 
(unpublished data). In adult bone marrow, a small subpopula-
tion (    21%) of the CD19  +  /surface IgM        pro–/pre–B cells 
expressed low levels of Fc    R on their cell surface, whereas 
    42% of the CD19  +  /surface IgM  +   B cells expressed slightly 
higher levels of Fc    R, indicating that Fc    R expression be-
gins at the pro–/pre–B cell stage in B-lineage diff  erentiation 
(  Fig. 8 D  ). No Fc    R expression was observed on myeloid cells 
even after overnight culture in IgM-free media. In contrast 
to the Fc    R phenotype of humans, our initial immuno-
fl  uorescence analysis of mouse splenocytes with a receptor-
specifi  c mAb revealed that Fc    R was expressed by B220  +   
B cells but not by CD3  +   T cells or Mac-1  +   macrophages (un-
published data). 
    Figure 8.     Immunofl  uorescence analysis of cell-surface Fc    R expression in various tissues.   (A–D) MNCs from blood (A and B), tonsils (C), and bone 
marrow (D) were fi  rst incubated with aggregated human IgG to block Fc    Rs and then with biotin-labeled HM14 anti-Fc    R mAb along with the appropri-
ate fl  uorochrome-labeled mAbs specifi  c for CD19, IgM, IgD, CD38, CD3, CD4, CD8, or CD56. For IgM ligand binding, mouse IgM     and biotin-labeled rat 
anti–mouse      mAbs were sequentially added to MNCs without preincubation with aggregated IgG. The bound biotin-labeled reagents were detected by 
addition of SA-PE. Essentially the same results were obtained with the HM7 anti-Fc    R mAb (not depicted). Because the results of the Fc    R expression by 
CD3  + /CD8 +   and CD3  + /CD4       T cells were essentially the same, the CD8 data were omitted for simplicity. The cell populations indicated by the red boxes 
were gated and examined for their reactivity with the HM14 anti-Fc    R mAb and IgM ligand. Biotin-labeled irrelevant mAbs of the    1    (for HM14) or 
   2b    (for HM7) isotype were used as controls. The analysis was performed with freshly prepared cell preparations (A and D; labeled Fresh) or with cells 
cultured overnight in IgM-free media (O/N; B and C). Because the immunofl  uorescence profi  les of freshly prepared tonsillar B cells with anti-Fc   R  mAbs 
and isotype-matched control mAbs as well as these of overnight-cultured B cells with the isotype-matched control mAbs were all essentially the same, 
only the results of freshly prepared and overnight-cultured B cells with anti-Fc    R mAbs are shown in C (top) for simplicity. CD19  +   B cells in tonsils 
(C) were analyzed for Fc    R expression as follicular/naive (IgD  + /CD38      ), pregerminal center (preGC; IgD  + /CD38 +  ), germinal center (GC; IgD      /CD38 +  ), and mem-
ory (IgD      /CD38      ) cells. The frequency (%) of Fc   R +   cells in each cell type among 10 different blood samples was 62 ± 18 for CD19  +   B cells, 62 ± 13 for 
CD4  +   T cells, 43 ± 23 for CD8  +   T cells, and 19 ± 11 for CD56  +   NK cells (means ± SD). The frequencies (%) of Fc   R +   cells over the background staining with 
isotype-matched control mAbs in three tonsillar samples were 31 ± 7 for follicular/naive, 15 ± 3 for preGC, 10 ± 3 for GC, and 30 ± 12 for memory B cells, 
and 34 ± 6 for CD4  +   T and 51 ± 7 for CD8  +   T cells (means ± SD). The experiments were performed >10 times for A and B, 3 times for C, and 2 times for D.     2788 Fc     receptor identity in humans   | Kubagawa et al. 
protein was unexpected, because in our previous biochemical 
analysis, the Fc    R expressed on such pre–B cells was sensi-
tive to GPI-PLC, whereas the Fc    R on blood T cells was 
resistant (  Ohno et al., 1990  ;   Nakamura et al., 1993  ). An in-
tensive search for an alternatively spliced transcript encoding 
a GPI-linked form of Fc    R was unsuccessful but led to iden-
tifi  cation of an Fc    R splice variant lacking the transmem-
brane exon that may encode a soluble form of Fc    R with 
an   M    r   of     34 kD (unpublished data). Reexamination of the 
susceptibility of Fc    R to GPI-PLC treatment yielded an 
unequivocal result: the expression of Fc    R on both PMA-
activated 697 pre–B cells and T cell transductants was un-
changed after GPI-PLC treatment, whereas the surface 
expression of GPI-anchored CD73 or Thy-1/CD90 was re-
duced by 50–65%. Thus, the discrepancy is likely caused by 
the fact that the GPI-PLC available for our studies in 1990 
contained residual contaminating protease activity. 
  Unlike other FcRs, the Fc    R has a relatively long cyto-
plasmic tail containing three conserved tyrosine and fi  ve to 
nine conserved serine residues. We found that some of these 
tyrosine and serine residues are targets for phosphorylation 
after Fc    R ligation with IgM immune complexes or pervan-
adate treatment. Intriguingly, the phosphorylated Fc    R was 
found to migrate on SDS-PAGE faster than the unphosphor-
ylated form. One possible explanation for this is that such 
phosphorylation may cause a global structural change of 
Fc    R leading to increased mobility on SDS-PAGE. Al-
though phosphorylated proteins usually migrate slower than 
their unphosphorylated forms, CD45 on a myeloid cell line 
in fact exhibits enhanced mobility on SDS-PAGE after PMA-
induced phosphorylation (  Buzzi et al., 1992  ). Another expla-
nation may be proteolytic cleavage in the cytoplasmic tail of 
Fc    R after receptor ligation, as has been observed in the 
Fc    RIIA on platelets (  Gardiner et al., 2008  ). Fc    RIIA liga-
tion on platelets leads to activation of both the metallo-
protease that targets the collagen receptor GPVI to shed its 
ectodomain and the intracellular calpain that cleaves the cyto-
plasmic tail of Fc    RIIA to remove the immunoreceptor 
tyrosine-based activation motif–containing stub, suggesting a 
novel mechanism for platelet dysfunction by Fc    RIIA after 
immunological insult including IgG autoantibodies to plate-
lets. The precise mechanism for the enhanced migration of 
phosphorylated Fc    R awaits further investigation. 
  Nucleotide sequence analysis indicated that Fc    R and 
FAIM3/TOSO are identical, but we have clearly shown that 
the antiapoptotic activity of Fc    R in Fas-bearing Jurkat cells 
is only observed when agonistic anti-Fas mAb of an IgM but 
not IgG  3   isotype is used and that the Fc    R expression itself 
does not prevent Fas-mediated apoptosis. Addition of a 100-
fold molar excess of control IgM into these cultures did not 
convert the Fc    R  +  GFP  +   cells from resistance to sensitivity 
to IgM anti-Fas mAb–induced apoptosis. Even when Fc    R 
and Fas on Fc    R  +   cells were brought into close physical 
proximity by ligation with a common secondary antibody, 
Fc    R did not inhibit Fas-mediated apoptosis. Notably, 
  Hitoshi et al.   (  1998  ) found that a FAIM3/TOSO deletion 
are sensitive to IgM ligand concentration, tissue milieu, and 
cellular activation status. 
  DISCUSSION 
  We have identifi  ed for the fi  rst time a bona fi  de Fc    R cDNA 
in humans. By using receptor-specifi  c mAbs and IgM ligands, 
Fc    R is defi  ned as an     60-kD transmembrane sialoglyco-
protein. Its predicted structure consists of a single V-set 
Ig-like domain with homology to the Ig-binding domains of 
pIgR and Fc    /μR, an additional extracellular region with no 
known domain features, a transmembrane segment contain-
ing a charged His residue, and a relatively long cytoplasmic 
tail carrying conserved Tyr and Ser residues. Pentameric IgM 
and its Fc  5  μ fragments bound cell-surface Fc    R on transduc-
tants, but the Fabμ fragments and other Ig isotypes did not, 
thereby confi  rming the Fc     specifi  city of this receptor. The 
affi   nity of the Fc    R for its IgM ligand is strikingly high, 
    10 nM. Despite the initial designation of Fc    R as an anti-
apoptotic protein FAIM3/TOSO, Fc    R per se had no in-
hibitory activity in Fas-mediated apoptosis, and such inhibition 
was only achieved when agonistic anti-Fas antibody of an 
IgM but not IgG isotype was used for inducing apoptosis. 
The cell types expressing Fc    R were predominantly B and 
T cells and not phagocytes; hence, the cellular distribution of 
Fc    R is quite distinct from that of other FcRs. The surface 
Fc    R levels on those lymphocytes were susceptible to IgM 
ligand concentration, tissue milieu. and cellular activation. 
  The   FCMR   gene is found to be in an appropriate loca-
tion on chromosome 1q32.2 adjacent to two other IgM-
binding receptor genes (  PIGR   and   FCAMR  ). Although the 
ligand-binding domains of these three receptors are similar to 
each other, Fc    R seems to be the most distantly related 
among the group based on the following fi  ndings. (a) Many 
residues are well conserved in pIgR and Fc    /μR but not in 
Fc    R. (b) The length of the CDR1 region, which is pre-
dicted to contact the Ig ligands, is shorter in Fc    R (5 aa) than 
in pIgR and Fc    /μR (9 aa). (c) Within the CDR1 region, 
there are two charged residues: Arg31 conserved in both 
pIgR and Fc    /μR, and His32 conserved in all three recep-
tors. Although Arg31 is predicted to be solvent exposed and 
to interact directly with polymeric IgA (  Hamburger et al., 
2004  ), Fc    Rs from seven diff  erent species have a noncharged 
residue at the corresponding position. (d) Fc    R recognizes 
only the IgM isotype, whereas both pIgR and Fc    /μR in 
humans bind polymeric IgA and IgM (  Kaetzel, 2005  ;   Kikuno 
et al., 2007  ). These fi  ndings thus suggest that the interaction 
of Fc    R with its IgM ligand is distinct from that of pIgR and 
Fc    /μR with IgM and polymeric IgA. In this regard, the 
fi  nding that Fc  5       fragments mostly consisting of the C    3/
C    4 domains inhibit IgM binding to Fc    R suggests that 
Fc    R recognizes a molecular confi  guration on IgM that is 
conferred by the C    3/C    4 domains. In contrast, pIgR rec-
ognizes the C-terminal domain C    4 (  Kaetzel, 2005  ). 
  The fi   nding that the Fc    R cDNAs identifi   ed in two 
cDNA libraries from PMA-activated 697 pre–B cells and 
CLL B cells encode a transmembrane but not a GPI-linked JEM VOL. 206, November 23, 2009 
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consistent with the results previously reported by others 
(  Pricop et al., 1993  ;   Rabinowich et al., 1996  ). The physio-
logical relevance of such restricted cellular expression of 
Fc    R may be related to unique features of the IgM ligand, 
such as its early appearance during immune responses, the 
pentameric confi  guration of its secreted form, and its potency 
in complement activation. 
  Many investigators had previously noticed the instability 
of IgM binding by B, T, and NK cells (  Moretta et al., 1977  ; 
  Nakamura et al., 1993  ;   Pricop et al., 1993  ). We also found 
that the cell-surface Fc    R levels were sensitive to extracellu-
lar IgM concentration, tissue milieu, and cellular activation 
status. This vulnerability could explain why Fc    R was lim-
ited to an operationally defi  ned entity for such a long time. 
As is the case with many other receptors, the detection of 
Fc    R with IgM ligands was much less effi   cient than with 
anti-Fc    R mAbs. Short-term culture in IgM-free media en-
hanced the cell-surface expression of Fc    R on T cells and, to 
a lesser extent, on B and NK cells. Remarkably, this phe-
nomenon was much more pronounced with cells from tonsils 
and spleen; cell-surface Fc    R was not detectable on freshly 
isolated B and T cells from these organs but easily demon-
strated after overnight culture in IgM-free media. Many other 
cell-surface antigens were detectable in those freshly isolated 
preparations, ruling out an artifact of tissue manipulation. To 
our knowledge, the IgM concentration in the interstitial spaces 
of such intact tissues has never been determined. If this in vivo 
down-modulation of Fc    R is solely dependent on the extra-
cellular concentration of IgM and not on the tissue microenvi-
ronment (e.g., proteases) or cellular activation status, then the 
interstitial IgM concentration in secondary lymphoid tissues is 
perhaps higher than in blood. In this regard, it is noteworthy 
that IgM-producing plasma cells are in the immediate vicinity 
of B and T cells within these lymphoid tissues. 
  Although both B and T cells express Fc    R, there is a 
striking diff  erence in their response after antigen receptor li-
gation. Fc    R expression on B cells was up-regulated after 
treatment with anti-μ mAb, whereas its expression on T cells 
was down-modulated after treatment with anti-CD3 mAb. 
The response to PMA was also diff  erent in the B and T cells, 
suggesting that the difference might be attributed to the 
downstream events involving PKC. The role of PKC in in-
ternalization of cell-surface receptors including TCR has been 
clearly demonstrated (  Cantrell et al., 1985  ;   Minami et al., 
1987  ;   Bonefeld et al., 2003  ). PKC is a conserved family of 11 
serine/threonine protein kinases, and most cell types express 
multiple isozymes of PKC (  Spitaler and Cantrell, 2004  ). PKC 
    ,   	  ,     ,     ,     ,   
  , and      are known to be present in lympho-
cytes. Interestingly, the disruption of the gene encoding a single 
PKC isozyme expressed in both B and T cells (e.g., PKC 	        /     , 
PKC          /     , and PKC          /     ) often caused a selective immuno-
logical abnormality in only one of the cell types, suggesting 
compensatory or complementary functions of other PKC iso-
zymes in the other cell type (  Spitaler and Cantrell, 2004  ). 
Based on the consensus sequence motifs, there are several po-
tential Ser residues available for phosphorylation by PKC in 
mutant lacking most of its cytoplasmic tail could still inhibit 
apoptosis mediated by IgM anti-Fas mAb, implying that 
FAIM3/TOSO might act indirectly through noncovalent 
association with another cell-surface protein. This might be 
relevant to our fi  nding that an additional membrane protein 
of     40 kD often coprecipitated with the     60-kD Fc    R 
from membrane lysates of Fc    R  +   cells and that there is a 
charged His residue, which could be involved in electrostatic 
association with other proteins, adjacent to the transmem-
brane segment of Fc    R. We therefore propose that the orig-
inal designation of this gene as   FAIM3/TOSO   should be 
reconsidered and that renaming it   FCMR   would be more 
appropriate in keeping with its true physiological role. 
  Another reason to rename this gene is that several groups 
(  Pallasch et al., 2008  ;   Proto-Siqueira et al., 2008  ) have re-
cently reported that   FAIM3/TOSO   is overexpressed in CLL, 
a heterogeneous leukemia thought to originate from anti-
gen-stimulated B cells that escape normal cell-death mecha-
nisms. The interpretation of this fi  nding by both groups is 
that the resistance of CLL B cells to death mechanisms may 
result from the enhanced expression of “antiapoptotic” FAIM3/
TOSO molecules. However, enhanced Fc    R expression by 
CLL B cells had been consistently observed by many investi-
gators using either rosetting or immunofl  uorescence meth-
ods (  Ferrarini et al., 1977  ;   Pichler and Knapp, 1977  ;   Sanders 
et al., 1987  ). Although the mechanism for enhanced Fc    R 
expression on CLL cells is unclear, it may result from chronic 
antigenic stimulation as supported by (a) reduced levels of 
membrane IgM, IgD, and CD79/Ig    /Ig  	   on CLL cells and 
(b) polyreactivity of CLL-derived IgM molecules (  Chiorazzi 
et al., 2005  ). In this regard, our fi  nding that treatment of 
normal blood B cells with anti-     antibody down-modulates 
membrane IgM and up-regulates Fc    R cell-surface expres-
sion is consistent with the hypothesis that CLL cells are being 
activated by certain common antigens; thereby, antigen-driven 
proliferation may provide an alternative mode of survival of 
the leukemic cells. 
  The fi  nding that the major cell types expressing Fc    R are 
the adaptive immune cells, both B and T lymphocytes, is re-
markable, because FcRs for the switched Ig isotypes (Fc    Rs, 
Fc    RI, and Fc    R) are expressed by various hematopoietic 
cells, including phagocytes, and are thought to be central me-
diators coupling the innate and adaptive immune responses 
(  Nimmerjahn and Ravetch, 2008  ). Intriguingly, Fc    R is the 
only FcR constitutively expressed on T cells, which are gen-
erally negative for the expression of other FcRs. The expres-
sion of Fc    R by both CD4  +   and CD8  +   T cells is consistent 
with an early report that T cells forming rosettes with IgM-
coated erythrocytes included both cell types (  Reinherz et al., 
1980  ). For B cells, Fc    R is the only IgM-binding receptor 
expressed. Although the initial report indicated that Fc    /μR 
is expressed on B cells (  Shibuya et al., 2000  ), our subsequent 
analyses revealed that the major cell type expressing Fc    /μR 
was a follicular dendritic cell in both humans (  Kikuno et al., 
2007  ) and mice (unpublished data). A small subpopulation of 
blood CD56  +  /CD3        NK cells was also found to express Fc    R, 2790 Fc     receptor identity in humans   | Kubagawa et al. 
  Transfection, transduction, and screening.     The cDNA libraries were 
transfected into the ecotropic retroviral packaging cell line BOSC23 with 
FuGENE 6 (Roche). 2 d later, the culture supernatants containing viruses 
were collected and fi  ltered, and polybrene (Sigma-Aldrich) was added to a 
fi  nal concentration of 10 μg/ml before infecting the mouse thymoma line 
BW5147 at a ratio of     3 × 10  5   cells/ml of supernatants. After 2 d, infected 
BW5147 T cells were incubated with biotin-labeled human IgM     and then 
with antibiotin microbeads (Miltenyi Biotec) or PE-labeled SA (Southern-
Biotech) before sorting IgM-binding cells by MACS or FACS, respectively. 
Enrichment of IgM-binding cells was repeated three times for MACS and 
once for FACS within the interval of     3 d, and the fi  nal FACS-sorted cells 
were cloned by limiting dilution. 
  Identifi  cation of cDNA inserts and sequencing.     Total RNA isolated 
from single-cell derived, IgM-binding and -nonbinding subclones was con-
verted to fi  rst-strand cDNA with a primer (5  
  -CCCTTTTTCTGGAGAC-
TAAAT-3  
  ) corresponding to the 3  
   vector sequence fl  anking the cloning 
site and SuperScript II RT (Invitrogen). The resultant fi  rst-strand cDNAs 
were used as template DNAs in PCR amplifi  cation with PrimeSTAR HS 
DNA polymerase (Takara Bio Inc.) and a set of primers corresponding to the 
5  
   and 3  
   fl  anking vector sequences of the cloning site, as previously de-
scribed (  Arase et al., 2001  ). Amplifi  ed PCR products were subcloned into 
the ZeroBlunt TOPO vector (Invitrogen) before sequencing analysis was 
performed at our institutional sequencing core facility using a DNA analyzer 
(model 3730xl) and DNA Sequencing Analysis Software (version 5.2; both 
from Applied Biosystems). 
  Preparation of Fc    R stable transductants.     Total RNAs isolated from 
PMA-activated 697 pre–B cells, CLL B cells, and tonsils were similarly con-
verted to fi  rst-strand cDNA with an oligo(dT)  18   primer, and the resultant 
fi  rst-strand cDNAs were used as template DNAs for amplifi  cation of Fc    R 
cDNA with a set of primers (forward, 5  
  -  AGATCT  AGAAGGGACAATG-
GACT-3  
  , and reverse, 5  
  -  GAATTC  TCAGGCAGGAACATTGATGT-3  
  ; 
underlined portions indicate   Bgl  II and   Eco  RI sites). Amplifi  ed products of the 
expected size of     1.2 kb were subcloned into the   Bam  HI and   Eco  RI sites of 
the pMXsPIE retroviral vector that contains a GFP cDNA and   Streptomyces al-
boniger   puromycin-  N  -acetyltransferase cDNA (a gift of A. Mui; DNAX, San 
Francisco, CA;   Ehrhardt et al., 1999  ). After confi  rming sequence identity, the 
ligated Fc    R cDNA construct and the empty vector were similarly trans-
duced in BW5147 T cells, and the GFP  +   cells in both transductants were en-
riched by FACS and in the presence of 1 μg/ml puromycin. For Fc    R  +   Jurkat 
cells, both the Fc    R/GFP and GFP-only constructs were transfected into the 
293T-A amphotropic packaging cell line before transducing the human Jurkat 
T cell line. GFP  +   cells were enriched three times by FACS before establishing 
the stable cell lines. In some experiments, both Fc    R/GFP and GFP con-
structs were similarly transfected into an appropriate packaging cell line and 
transduced into WEHI231 mouse B cells and Ramos human B cells. 
  Ig ligands and binding assay.     Human IgM myeloma proteins were puri-
fi  ed from serum samples by euglobulin fractionation and Sephacryl S-300 gel 
fi  ltration column chromatography (GE Healthcare;   Ohno et al., 1990  ). The 
Fc  5       and Fab     fragments were prepared from a human IgM     by hot trypsin 
digestion (  Plaut and Tomasi, 1970  ;   Ohno et al., 1990  ;   Nakamura et al., 
1993  ). Other human myeloma Igs of each isotype (    1,     2,     3,     4,     1,     2, 
    , and     ) and mouse myeloma IgM were purchased from EMD and Sigma-
Aldrich. The purity of IgM, its fragments, and other myeloma Igs was con-
fi  rmed by SDS-PAGE under both reducing and nonreducing conditions. 
Protein concentration was determined by absorbance at 280 nm with an ex-
tinction coeffi   cient of 1.4 as 1 mg/ml. For the binding inhibition assay, 
Fc    R  +   BW5147 T cells were incubated with various concentrations of Ig 
preparations along with a constant amount of biotin-labeled IgM    , washed, 
and incubated with PE-labeled SA to determine the bound IgM. 
  Production of hybridoma mAbs.     BALB/c mice were hyperimmunized 
subcutaneously with BW5147 T cells expressing human Fc    R, and regional 
lymph node cells were fused with the Ag8.653 plasmacytoma line, as previously 
the human Fc    R, particularly R-R-K-A-L-S283-R-R or 
A-P-S359-L-K. Thus, it seems possible that Fc    R expressed 
on B and T cells may have distinct infl  uences on their respec-
tive antigen receptor–mediated signaling. 
  With regard to the function of Fc    R on B cells, it has 
been shown that passive administration of IgM antibody, in 
contrast to IgG, enhances the subsequent antibody response 
to relevant antigenic challenge (  Hjelm et al., 2006  ). Recent 
studies with mice unable to produce the soluble form of IgM 
have clearly demonstrated the importance of secreted IgM in 
development of protective IgG antibody responses to viral 
and bacterial infections, presumably through both comple-
ment and Fc    R systems (  Boes et al., 1998a  ;   Boes et al., 1998b  ; 
  Ehrenstein et al., 1998  ;   Ochsenbein et al., 1999  ;   Baumgarth 
et al., 2000  ). The complement cleavage products C3dg and 
C3d attach covalently to antigen and cross-link both CD21 
(CR2) and BCR on the membrane of B cells, thereby facili-
tating the B cell response to low concentrations of antigen 
despite the typically low affi   nity of BCR during the primary 
immune response (  Fearon and Carter, 1995  ;   Fearon and Carroll, 
2000  ). The enhancing or adjuvant activity of C3d has been 
demonstrated with various antigens, although recently the 
inhibitory activity of C3d has also been reported for certain 
antigens (  Bergmann-Leitner et al., 2006  ). Given that IgM 
antibody is a fi  rst line of host defense, it is reasonable to pro-
pose that Fc    R may contribute to enhancement of B cell 
responses by interacting with BCR and CD21/CD19/CD81 
via IgM–antigen–C3d complexes. Another potential role for 
Fc    R on B cells is antigen presentation. The functional sig-
nifi  cance of Fc    R on T cells has been the subject of consid-
erable speculation (  Moretta et al., 1977  ;   Mathur et al., 1988b  ; 
  Nakamura et al., 1993  ). It seems possible that Fc    R on 
T cells may interact with the IgM BCR or IgM/antigen 
complexes on B cells to facilitate T and B cell interactions, 
thereby enhancing B cell activation. Fc    R may also trigger 
cytotoxic T cells in IgM antibody–dependent cell-mediated 
cytotoxicity. The true physiological roles of Fc    R, how-
ever, will become apparent with further studies, including 
analysis of the immunological phenotypes in Fc    R-defi  -
cient mice. Although the molecular nature of the Fc    R has 
long been elusive, its fi  nal unveiling in this study reveals a 
receptor full of intriguing aspects and opens new avenues 
of investigation. 
  MATERIALS AND METHODS 
  Construction of retroviral cDNA libraries.     The cDNA libraries were 
constructed by a cDNA synthesis kit (Agilent Technologies) using poly(A)  +   
RNA isolated by an Oligotex mRNA purifi  cation kit (QIAGEN) from (a) 
blood MNCs from a patient with CLL and (b) the 697 pre–B cell line preac-
tivated with 10 nM PMA for 8 h, as previously described (  Kubagawa et al., 
1997  ). The   Eco  RI/  Xho  I-digested and size-fractionated cDNAs were ligated 
into the pMXsΔN/S retrovirus vector, in which the 1,328-bp   Not  I/  Sal  I 
fragment containing an IRES and a GFP cDNA was removed from the 
original pMXsIG vector (  Kitamura et al., 2003  ). The ligated cDNA con-
structs were used to transform XL2-Blue MRF  
   ultracompetent cells (Agi-
lent Technologies). The titer of the cDNA library was     10  5   and     10  6   
CFU/μg mRNA for CLL and 697 pre–B cells, respectively, and the mean 
size of the insert DNA in these libraries was     1.6 kb. JEM VOL. 206, November 23, 2009 
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30 min before solubilizing in 200 μl of 1% NP-40 lysis buff  er. The cleared 
lysates were subjected to immunoprecipitation with HM14 or AM3 mAb–
coupled beads, and the bound materials were similarly analyzed by immuno-
blotting. Immunoblotted membranes were visualized by ECL. After dissociating 
the blotting antibodies, the membranes were reblotted with biotin-labeled anti-
Fc    R mAbs (HM14 and HM7) to confi  rm the phosphorylation of Tyr and 
Ser residues of Fc    R. 
  Apoptosis assay.     4 × 10  5   cells/ml were cultured for 24 h in RPMI 1640 
containing 10% FCS, penicillin/streptomycin, and 5 × 10      5   M 2-ME in the 
presence or absence of either of the agonistic anti-Fas mAbs, CH11 (10 ng/ml; 
mouse μk isotype; Millipore) or 2R2 (300 ng/ml; mouse     3    ; Invitrogen), 
washed twice with PBS, and incubated with 7-AAD and allophycocyanin 
(APC)-labeled annexin V for detecting apoptotic cells according to the man-
ufacturer’s recommendation (BD). In some experiments, 100-fold molar ex-
cess of human or mouse IgM myeloma protein as a ligand was added in these 
cultures. In other experiments, cells were preincubated with the 2R2 anti-
Fas mAb (300 ng/ml) and either F(ab  
  )  2   fragments or the intact form of the 
HM14 anti-Fc    R mAb (50 μg/ml) for 20 min at 4°C, washed, and cultured 
in the presence or absence of F(ab  
  )  2   fragments of goat anti–mouse      anti-
bodies (50 μg/ml) overnight at 37°C. 
  Scatchard plot analysis.     2 × 10  6   Fc    R  +   BW5147 T cells were incubated 
in triplicate with serial dilutions of   125  I-labeled IgM with a specifi  c activity of 
    1.6 × 10  17   cpm/mol in 30 μl PBS containing 3% FCS and 0.2% sodium 
azide for 1.5 h at room temperature before washing and aspirating unbound 
IgM by centrifugation. Some tubes contained a 200-fold molar excess of 
cold IgM to determine the amounts of nonspecifi  c binding of   125  I-labeled 
IgM to cells. The numbers of IgM molecules specifi  cally bound per cell were 
plotted on the x axis against the ratio of bound to free IgM on the y axis, and 
the apparent dissociation constant was obtained by dividing the number of 
receptors per cell by the bound/free ratio at the y-axis intercept, as previ-
ously described (  Lowenthal et al., 2001  ). 
  Online supplemental material.     Fig. S1 shows the nucleotide sequence of 
the human Fc    R cDNA. Fig. S2 shows the defi  nition of FAIM3/TOSO as 
an Fc    R. Fig. S3 shows the predicted protein structure of human Fc    R. Fig. S4 
shows the eff  ects of Fc    R ligation on anti-Fas antibody–mediated apopto-
sis in Jurkat T cells. Fig. S5 shows the expression of cell-surface Fc    R on 697 
pre–B cell line before and after PMA stimulation. Fig. S6 shows   FCMR   gene 
expression analyzed by RT-PCR. Fig. S7 shows the lack of Fc    R expres-
sion by monocytes, granulocytes, erythrocytes, and platelets. Fig. S8 shows 
enhanced Fc    R expression on CLL cells. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20091107/DC1. 
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described (  Kikuno et al., 2007  ). Hybridoma clones producing IgG mAbs 
reactive with Fc    R  +   BW5147 T cells, but not with Fc    /    R  +   BW5147 
T cells, control BW5147 T cells, and pIgR  +   FT-29 cells were selected and 
subcloned by limiting dilution. Two human Fc    R-specifi  c mAbs, HM7 
(    2b    ) and HM14 (    1    ), were selected in this study. Their F(ab  
  )  2   fragments 
were prepared by digestion with lysyl endopeptidase (  Yamaguchi et al., 1995  ) 
and pepsin (  Maruyama et al., 1985  ) for HM7 and HM14, respectively. 
  Flow cytometric analysis of cells.     Blood MNCs were isolated by Ficoll-
Hypaque density gradient centrifugation. Granulocytes were isolated from 
erythrocyte pellets by diff  erential sedimentation in 1.5% dextran in PBS. 
MNCs were also prepared from long bone, tonsil, and spleen tissues ob-
tained from our institutional tissue procurement service. Approval for use of 
these human materials in this investigation was obtained from the University 
of Alabama at Birmingham Institutional Review Board. Cells were fi  rst in-
cubated with aggregated human IgG to block Fc    Rs and then stained with 
biotin-labeled anti-Fc    R mAbs along with fl  uorochrome-labeled  mAbs 
specifi  c for CD3, CD4, CD8, CD19, CD14, CD56, CD10, or CD13. 
PE-labeled SA was used as a developing reagent for biotinylated mAbs. Con-
trols included isotype-matched irrelevant mAbs labeled with the correspond-
ing fl  uorochromes or biotin. In some experiments, biotin-labeled F(ab  
  )  2   
fragments of anti-Fc    R mAbs were used. Stained cells were analyzed with a 
FACSCalibur instrument (BD). For GPI-PLC treatment, 10  6   cells were in-
cubated for 45 min at 30°C in 10 mM Hepes/HBSS (without Ca  2+   and 
Mg  2+  ) containing 10 U/ml GPI-PLC (Sigma-Aldrich). After treatment, cells 
were washed and examined for Fc    R and other cell-surface antigens by 
FACSCalibur. For neuraminidase treatment, 5 × 10  6   cells/ml in HBSS were 
incubated with 50 U/ml neuraminidase (New England Biolabs, Inc.) at 
37°C for 45 min before washing and immunofl  uorescence analysis. 
  Cell-surface biotinylation and immunoprecipitation analysis.     Plasma 
membrane proteins on 10  7   viable cells were labeled with 1 ml sulfo-NHS-
LC-biotin (0.1 mg/ml; Thermo Fisher Scientifi  c) in 0.15 M NaCl/0.1 M 
Hepes (pH 8) for 30 min at 25°C. After washing, biotinylated cells were in-
cubated with 10 μl anti-Fc    R or isotype-matched control mAbs or mouse 
IgM     ligand (50 μg/ml) for 20 min on ice, washed, and lysed in 200 μl of 1% 
NP-40 lysis buff  er containing protease inhibitors (  Sanders et al., 1987  ;   Ohno 
et al., 1990  ;   Nakamura et al., 1993  ). Cleared lysates were either transferred to 
96-well plates precoated with 20 μg/ml of rat anti–mouse      mAb (clone 
187.1;   Yelton et al., 1981  ) or incubated with rat anti–mouse      mAb–coupled 
beads, and the bound materials were dissociated and separated by SDS-PAGE 
under reducing and nonreducing conditions, followed by transfer to mem-
branes, blotting with horseradish peroxidase (HRP)–SA, and visualization by 
ECL (GE Healthcare), as previously described (  Kikuno et al., 2007  ). In some 
experiments, the anti-Fc    R mAb–bound materials were resuspended in 
7 M urea/2 M thiourea/4% CHAPS/40 mM dithiothreitol/0.5% ampholite 
(pH 3–10)/40 mM Tris-HCl (pH 8.8) and subjected to two-dimensional gel 
electrophoresis analysis, as previously described (  Ohno et al., 1990  ). 
  Immunoblot analysis.     To determine the phosphorylation status of Tyr 
and Ser residues in Fc    R, 3 × 10  7   cells serum starved for 1.5 h in RPMI 
1640/20 mM Hepes media were treated with 100 μM pervanadate for 
15 min at 37°C, lysed in 1 ml of 1% NP-40 lysis buff  er with protease/phospha-
tase inhibitors, and immunoprecipitated with Sepharose 4B beads coupled to 
HM14 anti-Fc    R mAb or AM3 anti-Fc    /    R mAb as an isotype-matched 
control. The bound materials were dissociated with 0.1 M glycine-HCl buf-
fer (pH 2.8) in 0.5% NP-40, immediately neutralized with 1 M Tris, and re-
solved on SDS–10% PAGE before transfer onto membranes. After soaking 
with 5% nonfat milk, membranes were immunoblotted with HRP-labeled 
antiphosphotyrosine mAb (4G10; Millipore) or rabbit antibody specifi  c for 
phosphoserine of PKC substrates (Cell Signaling Technology) along with 
HRP-labeled goat anti–rabbit Ig antibody (SouthernBiotech) as a develop-
ing reagent. For receptor ligation, serum-starved cells were incubated with 
50 μl of the preformed IgM immune complexes, an equal mixture of human 
IgM     myeloma protein (100 μg/ml) and F(ab  
  )  2   fragments of anti–human 
     mAb with specifi  city for the C    1 domain (50 μg/ml), at 37°C for 0, 3, and 2792 Fc     receptor identity in humans   | Kubagawa et al. 
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